Serum Dickkopf-1 (DKK1) is significantly lower in patients with lung cancer but is rapidly normalized after treatment

Heng Xu, Jianzhong Wu, Bo Chen, Meng Li, Yanna Tian, Mingfang He, Jing Xue, Jiangnan Wang, Shan Bai, Ashok Kumar Sharma, Haitao Liu, Jinhai Tang, Jin-Xiong She

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

DKK1 is a secreted glycoprotein that inhibits Wnt/β-catenin signaling but may up-regulate the nonconani-cal Wnt signaling. Consistent with its inhibitory function in Wnt/β-catenin signaling, aberrant DKK1 expression has been observed in many types of human cancers, while contradicting findings have been reported in other studies. There are also several studies on serum DKK1 levels in various cancers with conflicting findings. In the present study, serum DKK1 was determined in 217 non-small cell lung cancer (NSCLC) patients, 35 small cell lung cancer (SCLC) patients and 286 matched healthy controls using a commercially available ELISA assay kit. Compared to healthy controls, serum DKK1 level was significantly lower in NSCLC (p < 10 -28 ) and SCLC (p <10 -4 ) patients. Interestingly, serum DKK1 level was higher in NSCLC patients in stage IV (p < 0.0005), with lymph node involvement (p < 0.0002) or with metastasis (p < 0.0001), suggesting that DKK1 may promote metastasis. After surgery and/or chemotherapy, serum DKK1 level is rapidly increased and reached levels observed in healthy controls in most patients. The degree of post therapeutic DKK1 increase varied in different treatment regimens. Our results thus provide strong evidence for the reduced levels of serum DKK1 in both types of lung cancer. However, in the context of all published studies, DKK1 appears to have a dichotomous role in cancer and its effect in a given cancer type or even a given cancer patient is likely to depend on the molecular context of the patient.

Original languageEnglish (US)
Pages (from-to)850-856
Number of pages7
JournalAmerican Journal of Translational Research
Volume6
Issue number6
StatePublished - Jan 1 2014

Fingerprint

Catenins
Lung Neoplasms
Serum
Cells
Non-Small Cell Lung Carcinoma
Chemotherapy
Small Cell Lung Carcinoma
Surgery
Neoplasms
Assays
Glycoproteins
Therapeutics
Neoplasm Metastasis
Up-Regulation
Lymph Nodes
Enzyme-Linked Immunosorbent Assay
Drug Therapy

Keywords

  • Biomarker
  • DKK1
  • Lung cancer
  • WNT signaling

ASJC Scopus subject areas

  • Molecular Medicine
  • Clinical Biochemistry
  • Cancer Research

Cite this

Serum Dickkopf-1 (DKK1) is significantly lower in patients with lung cancer but is rapidly normalized after treatment. / Xu, Heng; Wu, Jianzhong; Chen, Bo; Li, Meng; Tian, Yanna; He, Mingfang; Xue, Jing; Wang, Jiangnan; Bai, Shan; Sharma, Ashok Kumar; Liu, Haitao; Tang, Jinhai; She, Jin-Xiong.

In: American Journal of Translational Research, Vol. 6, No. 6, 01.01.2014, p. 850-856.

Research output: Contribution to journalArticle

Xu, H, Wu, J, Chen, B, Li, M, Tian, Y, He, M, Xue, J, Wang, J, Bai, S, Sharma, AK, Liu, H, Tang, J & She, J-X 2014, 'Serum Dickkopf-1 (DKK1) is significantly lower in patients with lung cancer but is rapidly normalized after treatment', American Journal of Translational Research, vol. 6, no. 6, pp. 850-856.
Xu, Heng ; Wu, Jianzhong ; Chen, Bo ; Li, Meng ; Tian, Yanna ; He, Mingfang ; Xue, Jing ; Wang, Jiangnan ; Bai, Shan ; Sharma, Ashok Kumar ; Liu, Haitao ; Tang, Jinhai ; She, Jin-Xiong. / Serum Dickkopf-1 (DKK1) is significantly lower in patients with lung cancer but is rapidly normalized after treatment. In: American Journal of Translational Research. 2014 ; Vol. 6, No. 6. pp. 850-856.
@article{b546fd703de645799c287ed950af23a0,
title = "Serum Dickkopf-1 (DKK1) is significantly lower in patients with lung cancer but is rapidly normalized after treatment",
abstract = "DKK1 is a secreted glycoprotein that inhibits Wnt/β-catenin signaling but may up-regulate the nonconani-cal Wnt signaling. Consistent with its inhibitory function in Wnt/β-catenin signaling, aberrant DKK1 expression has been observed in many types of human cancers, while contradicting findings have been reported in other studies. There are also several studies on serum DKK1 levels in various cancers with conflicting findings. In the present study, serum DKK1 was determined in 217 non-small cell lung cancer (NSCLC) patients, 35 small cell lung cancer (SCLC) patients and 286 matched healthy controls using a commercially available ELISA assay kit. Compared to healthy controls, serum DKK1 level was significantly lower in NSCLC (p < 10 -28 ) and SCLC (p <10 -4 ) patients. Interestingly, serum DKK1 level was higher in NSCLC patients in stage IV (p < 0.0005), with lymph node involvement (p < 0.0002) or with metastasis (p < 0.0001), suggesting that DKK1 may promote metastasis. After surgery and/or chemotherapy, serum DKK1 level is rapidly increased and reached levels observed in healthy controls in most patients. The degree of post therapeutic DKK1 increase varied in different treatment regimens. Our results thus provide strong evidence for the reduced levels of serum DKK1 in both types of lung cancer. However, in the context of all published studies, DKK1 appears to have a dichotomous role in cancer and its effect in a given cancer type or even a given cancer patient is likely to depend on the molecular context of the patient.",
keywords = "Biomarker, DKK1, Lung cancer, WNT signaling",
author = "Heng Xu and Jianzhong Wu and Bo Chen and Meng Li and Yanna Tian and Mingfang He and Jing Xue and Jiangnan Wang and Shan Bai and Sharma, {Ashok Kumar} and Haitao Liu and Jinhai Tang and Jin-Xiong She",
year = "2014",
month = "1",
day = "1",
language = "English (US)",
volume = "6",
pages = "850--856",
journal = "American Journal of Translational Research",
issn = "1943-8141",
publisher = "e-Century Publishing Corporation",
number = "6",

}

TY - JOUR

T1 - Serum Dickkopf-1 (DKK1) is significantly lower in patients with lung cancer but is rapidly normalized after treatment

AU - Xu, Heng

AU - Wu, Jianzhong

AU - Chen, Bo

AU - Li, Meng

AU - Tian, Yanna

AU - He, Mingfang

AU - Xue, Jing

AU - Wang, Jiangnan

AU - Bai, Shan

AU - Sharma, Ashok Kumar

AU - Liu, Haitao

AU - Tang, Jinhai

AU - She, Jin-Xiong

PY - 2014/1/1

Y1 - 2014/1/1

N2 - DKK1 is a secreted glycoprotein that inhibits Wnt/β-catenin signaling but may up-regulate the nonconani-cal Wnt signaling. Consistent with its inhibitory function in Wnt/β-catenin signaling, aberrant DKK1 expression has been observed in many types of human cancers, while contradicting findings have been reported in other studies. There are also several studies on serum DKK1 levels in various cancers with conflicting findings. In the present study, serum DKK1 was determined in 217 non-small cell lung cancer (NSCLC) patients, 35 small cell lung cancer (SCLC) patients and 286 matched healthy controls using a commercially available ELISA assay kit. Compared to healthy controls, serum DKK1 level was significantly lower in NSCLC (p < 10 -28 ) and SCLC (p <10 -4 ) patients. Interestingly, serum DKK1 level was higher in NSCLC patients in stage IV (p < 0.0005), with lymph node involvement (p < 0.0002) or with metastasis (p < 0.0001), suggesting that DKK1 may promote metastasis. After surgery and/or chemotherapy, serum DKK1 level is rapidly increased and reached levels observed in healthy controls in most patients. The degree of post therapeutic DKK1 increase varied in different treatment regimens. Our results thus provide strong evidence for the reduced levels of serum DKK1 in both types of lung cancer. However, in the context of all published studies, DKK1 appears to have a dichotomous role in cancer and its effect in a given cancer type or even a given cancer patient is likely to depend on the molecular context of the patient.

AB - DKK1 is a secreted glycoprotein that inhibits Wnt/β-catenin signaling but may up-regulate the nonconani-cal Wnt signaling. Consistent with its inhibitory function in Wnt/β-catenin signaling, aberrant DKK1 expression has been observed in many types of human cancers, while contradicting findings have been reported in other studies. There are also several studies on serum DKK1 levels in various cancers with conflicting findings. In the present study, serum DKK1 was determined in 217 non-small cell lung cancer (NSCLC) patients, 35 small cell lung cancer (SCLC) patients and 286 matched healthy controls using a commercially available ELISA assay kit. Compared to healthy controls, serum DKK1 level was significantly lower in NSCLC (p < 10 -28 ) and SCLC (p <10 -4 ) patients. Interestingly, serum DKK1 level was higher in NSCLC patients in stage IV (p < 0.0005), with lymph node involvement (p < 0.0002) or with metastasis (p < 0.0001), suggesting that DKK1 may promote metastasis. After surgery and/or chemotherapy, serum DKK1 level is rapidly increased and reached levels observed in healthy controls in most patients. The degree of post therapeutic DKK1 increase varied in different treatment regimens. Our results thus provide strong evidence for the reduced levels of serum DKK1 in both types of lung cancer. However, in the context of all published studies, DKK1 appears to have a dichotomous role in cancer and its effect in a given cancer type or even a given cancer patient is likely to depend on the molecular context of the patient.

KW - Biomarker

KW - DKK1

KW - Lung cancer

KW - WNT signaling

UR - http://www.scopus.com/inward/record.url?scp=84912076499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912076499&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 850

EP - 856

JO - American Journal of Translational Research

JF - American Journal of Translational Research

SN - 1943-8141

IS - 6

ER -